Related Experiment Video
Updated: Aug 14, 2026

Measuring the Carotid to Femoral Pulse Wave Velocity (Cf-PWV) to Evaluate Arterial Stiffness
Published on: May 3, 2018
Achieving blood pressure targets in the management of hypertension
1Division of Pathophysiology and Medical Teaching, Centre Hospitalier Universitaire Vandois, Lausanne, Switzerland.
Insights
Achieving normal blood pressure is challenging, as less than one-third of patients worldwide are effectively treated. Combining therapies, like angiotensin II receptor antagonists (AIIRAs) with diuretics, improves blood pressure control and tolerability.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Current hypertension guidelines aim for blood pressure below 130/85 mmHg.
- Despite treatment efforts, less than one-third of hypertensive patients globally achieve normalized blood pressure.
- Treatment failure often results from ineffective or poorly tolerated antihypertensive therapies.
Purpose of the Study:
- To evaluate the efficacy and tolerability of antihypertensive drug regimens.
- To explore the role of angiotensin II receptor antagonists (AIIRAs) in managing hypertension.
- To assess the combination therapy of irbesartan and hydrochlorothiazide.
Main Methods:
- Review of antihypertensive therapy guidelines and treatment outcomes.
- Analysis of the efficacy of angiotensin II receptor antagonists (AIIRAs) as monotherapy.
- Evaluation of irbesartan in combination with hydrochlorothiazide for blood pressure reduction.
Main Results:
- AIIRAs offer blood pressure reduction comparable to other antihypertensives with superior tolerability.
- Irbesartan demonstrates dose-related efficacy in monotherapy.
- Combination therapy with irbesartan and low-dose hydrochlorothiazide enhances antihypertensive efficacy.
Conclusions:
- Hypertension management requires effective and well-tolerated treatment regimens.
- Combination therapy, particularly with AIIRAs like irbesartan, can improve blood pressure control.
- Personalized drug regimens are crucial for normalizing blood pressure in all hypertensive patients.
Abstract:
The 1999 World Health Organization-International Society of Hypertension guidelines state that the goal of antihypertensive therapy should be to restore blood pressure to a level defined as normal (<130/85 mmHg). Yet, despite significant efforts in diagnosing and treating hypertension, blood pressure is normalized in less than one-third of hypertensive patients worldwide. Inadequate blood pressure control is most likely to occur when treatment is ineffective, intolerable or both. Hypertension is a heterogeneous disease involving several pressor systems. It is therefore not surprising that a single drug normalizes blood pressure in only a fraction of hypertensive patients. Co-administering two medications that lower blood pressure by different mechanisms generally increases antihypertensive efficacy. The angiotensin II receptor antagonist (AIIRA) class represents a new therapeutic option: a class of agents that provide blood pressure reduction similar to other classes of antihypertensives with the additional advantage of an excellent tolerability profile. The AIIRA irbesartan has demonstrated dose-related efficacy in reducing blood pressure as monotherapy and augmented efficacy in combination with low doses of the diuretic hydrochlorothiazide. Efforts should be directed to normalize blood pressure in every hypertensive patient by finding a drug regimen that is simultaneously effective and well tolerated.
Related Concept Videos
Factors affecting Blood pressure
Physiological Factors:
Errors occurring during blood pressure monitoring
Several factors...
Hypertension and Regulation of Blood Pressure
Hypertension I: Introduction
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension V: Nursing Management

